

# Kyrollis Attalla

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4649480/publications.pdf>

Version: 2024-02-01

29  
papers

634  
citations

759233

12  
h-index

642732

23  
g-index

29  
all docs

29  
docs citations

29  
times ranked

885  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell sequencing links multiregional immune landscapes and tissue-resident T <sup>A</sup> cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	16.8	179
2	The evolution of bladder cancer genomics: What have we learned and how can we use it?. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 313-320.	1.6	73
3	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	12.8	46
4	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. <i>European Urology</i> , 2021, 79, 468-477.	1.9	35
5	Oxalate Content of Food: A Tangled Web. <i>Urology</i> , 2014, 84, 555-560.	1.0	33
6	Prospective implementation of a nonopioid protocol for patients undergoing robot-assisted radical cystectomy with extracorporeal urinary diversion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 300.e17-300.e23.	1.6	28
7	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	3.1	28
8	Reevaluating Warm Ischemia Time as a Predictor of Renal Function Outcomes After Robotic Partial Nephrectomy. <i>Urology</i> , 2018, 120, 156-161.	1.0	26
9	Epidemiology, Risk Assessment, and Biomarkers for Patients with Advanced Renal Cell Carcinoma. <i>Urologic Clinics of North America</i> , 2020, 47, 293-303.	1.8	25
10	Demographic and socioeconomic predictors of treatment delays, pathologic stage, and survival among patients with penile cancer: A report from the National Cancer Database. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 14.e17-14.e24.	1.6	22
11	Phase II Study of Neoadjuvant Nivolumab in Patients with Locally Advanced Clear Cell Renal Cell Carcinoma Undergoing Nephrectomy. <i>European Urology</i> , 2022, 81, 570-573.	1.9	22
12	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	5.4	20
13	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. <i>British Journal of Anaesthesia</i> , 2020, 125, e402-e404.	3.4	15
14	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5595-5606.	7.0	12
15	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. <i>Cancer</i> , 2021, 127, 3946-3956.	4.1	12
16	TIM-3 and TIGIT are possible immune checkpoint targets in patients with bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 403-406.	1.6	9
17	Possible Detrimental Effects of Clamping Main Versus Segmental Renal Arteries for the Achievement of Renal Global Ischemia During Robot-Assisted Partial Nephrectomy. <i>Journal of Endourology</i> , 2015, 29, 785-790.	2.1	8
18	Management of distal ureter and bladder cuff at the time of nephroureterectomy: surgical techniques and predictors of outcome. <i>Future Oncology</i> , 2019, 15, 2385-2393.	2.4	7

#	ARTICLE	IF	CITATIONS
19	Radiogenomics in Clear Cell Renal Cell Carcinoma: A Review of the Current Status and Future Directions. <i>Cancers</i> , 2022, 14, 2085.	3.7	7
20	Seasonal variations in urinary calcium, volume, and vitamin D in kidney stone formers. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2018, 44, 947-951.	1.5	5
21	Current Role of Checkpoint Inhibitors in Urologic Cancers. <i>Cancer Treatment and Research</i> , 2018, 175, 241-258.	0.5	5
22	Survival of Patients with Muscle-Invasive Urothelial Cancer of the Bladder with Residual Disease at Time of Cystectomy: A Comparative Survival Analysis of Treatment Modalities in the National Cancer Database. <i>Bladder Cancer</i> , 2020, 6, 265-276.	0.4	5
23	Leiomyosarcoma of the Inferior Vena Cava With Kidney Invasion. <i>Urology Case Reports</i> , 2016, 9, 33-36.	0.3	3
24	Robotic-assisted radical cystectomy versus open radical cystectomy for management of bladder cancer: review of literature and randomized trials. <i>Future Oncology</i> , 2017, 13, 1195-1204.	2.4	3
25	A qualitative framework of non-selection factors for cytoreductive nephrectomy. <i>World Journal of Urology</i> , 2021, 39, 3359-3365.	2.2	3
26	Squamous Cell Carcinoma of the Renal Pelvis: Atypical Presentation of a Rare Malignancy. <i>Urology Case Reports</i> , 2017, 13, 137-139.	0.3	2
27	The spinal distribution of metastatic renal cell carcinoma: Support for locoregional rather than arterial hematogenous mode of early bony dissemination. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 196.e9-196.e14.	1.6	1
28	Prolonged hormonal therapy and external beam radiation independently increase the risk of Persistent Hypogonadism in men treated with prostate brachytherapy. <i>Brachytherapy</i> , 2020, 19, 210-215.	0.5	0
29	Prognostic models in papillary renal cell carcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 1334.	1.7	0